Toxic skin reaction - Symptoms, Causes, Treatment & Prevention

```html

Overview

Toxic skin reaction (also called a toxic skin eruption, drug‑induced toxic erythema, or severe cutaneous adverse reaction) is an abnormal, often sudden, inflammatory response of the skin to a chemical, medication, or environmental toxin. The reaction can range from mild redness to life‑threatening conditions such as Stevens‑Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Although the term “toxic skin reaction” is sometimes used loosely, clinicians typically reserve it for reactions that involve widespread erythema, bullae, or desquamation that occur after exposure to a known trigger.

• Who it affects: Anyone can develop a toxic skin reaction, but most cases occur in adults aged 30‑70 years who are taking prescription medications or have occupational exposure to chemicals.
• Prevalence: Severe drug‑induced reactions (SJS/TEN) affect roughly 1–2 per 1,000,000 people per year in the United States, while milder toxic eruptions are far more common—estimated at 2–4 % of patients receiving high‑risk drugs such as antibiotics, anticonvulsants, or allopurinol <sup>[1][2]</sup>.
• Why it matters: Early recognition can prevent progression to extensive skin loss, systemic organ damage, and death (mortality rates for TEN range from 25–35 %).

Symptoms

The clinical picture varies with severity, but the following signs are frequently reported. Look for any combination that appears shortly after a new medication, chemical exposure, or an unexplained environmental change.

• Generalized erythema: Diffuse redness that may feel warm or pruritic.
• Maculopapular rash: Flat red spots (macules) mixed with raised bumps (papules). Often starts on the trunk and spreads outward.
• Pruritus (itching): Can be mild or severe; scratching may exacerbate skin damage.
• Edema: Swelling of the face, lips, or extremities.
• Target lesions: Concentric rings resembling a bullseye (classic for erythema multiforme, a milder form).
• Blistering (bullae): Fluid‑filled vesicles that can coalesce into larger bullae; a hallmark of SJS/TEN.
• Skin sloughing (desquamation): Peeling skin that may look like a sunburn or a “peel” of parchment; in TEN, >30 % of body surface area (BSA) is involved.
• Mucosal involvement: Painful erosions of the mouth, eyes, genitalia, or respiratory tract; present in >90 % of SJS/TEN cases.
• Systemic symptoms: Fever, chills, malaise, headache, or myalgias—often precede the rash by 1‑3 days.
• Laboratory abnormalities: Elevated eosinophils, liver enzymes, or renal markers may accompany severe reactions.

Causes and Risk Factors

Most toxic skin reactions are triggered by external agents rather than inherent skin disease. The leading categories are:

Medications

• Antibiotics (e.g., sulfonamides, penicillins, fluoroquinolones)
• Anticonvulsants (e.g., carbamazepine, lamotrigine, phenytoin)
• Allopurinol (used for gout)
• Non‑steroidal anti‑inflammatory drugs (NSAIDs)
• Antiretrovirals and some chemotherapeutic agents

Chemical or Environmental Exposures

• Industrial solvents, dyes, or pesticides (often occupational)
• Cosmetics containing fragrance allergens or preservatives (e.g., formaldehyde releasers)
• Plant irritants (e.g., poison ivy, certain mushrooms) that can induce a systemic toxic response in sensitized individuals.

Infections

Viral infections (e.g., Mycoplasma pneumoniae, herpes simplex) can mimic or precipitate toxic eruptions, especially in children.

Risk Factors

• Genetic predisposition: Certain HLA alleles (e.g., HLA‑B*15:02 in Han Chinese for carbamazepine) dramatically increase risk <sup>[3]</sup>.
• Age and comorbidities: Elderly patients and those with renal/hepatic impairment have reduced drug clearance, raising toxicity risk.
• Polypharmacy: Taking multiple high‑risk drugs simultaneously amplifies the chance of a reaction.
• Previous drug reaction: A history of any cutaneous adverse drug reaction predisposes to future episodes.
• Immune status: Immunocompromised individuals (e.g., HIV, transplant recipients) may develop more severe eruptions.

Diagnosis

Diagnosis is primarily clinical, supported by a detailed history and targeted investigations.

History and Physical Exam

• Identify recent medication changes (within the past 1‑4 weeks) or chemical exposures.
• Document rash onset, progression, distribution, and associated systemic symptoms.
• Examine mucosal surfaces for erosions, which signal severe disease.

Laboratory Tests

• Complete blood count (CBC): May reveal eosinophilia or leukocytosis.
• Liver and kidney panels: Detect organ involvement.
• Serum electrolytes & albumin: Important in severe cases where fluid loss occurs.

Skin Biopsy

When the diagnosis is uncertain, a punch biopsy can differentiate toxic eruptions from other conditions (e.g., psoriasis, autoimmune bullous disease). Histology often shows interface dermatitis with necrotic keratinocytes in SJS/TEN.

Special Tests

• Patch testing: Useful for confirming allergic contact components after the acute phase.
• Pharmacogenetic screening: HLA‑B*15:02 or HLA‑A*31:01 testing before prescribing high‑risk drugs in susceptible populations.

Treatment Options

Treatment hinges on rapid cessation of the offending agent and supportive care. The therapeutic approach differs by severity.

Immediate Measures

1. Stop the trigger: Discontinue the suspected medication or remove exposure to the chemical.
2. Hospital admission: Required for extensive skin involvement (>10 % BSA), mucosal disease, or systemic symptoms.

Pharmacologic Therapy

• Corticosteroids: Short courses of oral or IV prednisone (0.5‑1 mg/kg) are often used for moderate reactions; high‑dose IV methylprednisolone may be considered in severe SJS/TEN, though evidence is mixed.
• Intravenous Immunoglobulin (IVIG): Doses of 2 g/kg over 2‑3 days have shown benefit in some SJS/TEN series by inhibiting Fas‑mediated keratinocyte apoptosis <sup>[4]</sup>.
• Ciclosporin: 3‑5 mg/kg/day can hasten skin healing and reduce mortality in TEN; increasingly favored due to lower infection risk compared with steroids.
• TNF‑α inhibitors (e.g., etanercept): Emerging data suggest they may improve outcomes in SJS/TEN by dampening inflammatory pathways.
• Antihistamines: Helpful for pruritus but do not alter disease course.

Supportive Care

• Wound management: Treat the skin like a burn—gentle cleansing, non‑adhesive dressings, and a moist environment to prevent infection.
• Fluid and electrolyte replacement: Intravenous fluids guided by daily weight and serum electrolytes.
• Nutrition: High‑protein diet or enteral feeding if oral intake is limited due to oral mucosal involvement.
• Eye care: Ophthalmology consult; lubricating drops, topical steroids, and, when needed, amniotic membrane grafts to prevent scarring.
• Pain control: Acetaminophen (avoid NSAIDs) and opioid analgesics as required.

Procedures

• Debridement: Rarely needed; only if necrotic tissue becomes a source of infection.
• Skin grafting: Considered in chronic phases when large areas fail to re‑epithelialize.

Living with Toxic Skin Reaction

Even after acute resolution, patients may face lingering issues. Here are practical strategies for daily life.

• Medication diary: Keep a detailed log of every drug (prescription, OTC, supplement) with start/stop dates.
• Skin moisturization: Apply fragrance‑free emollients (e.g., petrolatum, ceramide creams) at least twice daily to restore barrier function.
• Sun protection: Use broad‑spectrum SPF 30+ sunscreen; UV exposure can aggravate post‑inflammatory hyperpigmentation.
• Gentle skin care: Avoid harsh soaps, hot water, and tight clothing that can irritate healing skin.
• Psychological support: Anxiety, depression, or post‑traumatic stress are common after severe reactions; counseling or support groups are beneficial.
• Regular follow‑up: Dermatology visits every 2‑4 weeks until lesions fully resolve; lab monitoring if systemic involvement was present.
• Vaccination considerations: Discuss timing of live vaccines; some medications (e.g., immunosuppressants) may affect immune response.

Prevention

Reducing risk involves both patient‑level actions and clinician vigilance.

• Pharmacogenetic testing: Perform HLA‑B*15:02 screening before prescribing carbamazepine to Asian patients, and HLA‑A*31:01 for allopurinol in high‑risk groups.
• Medication reconciliation: Ensure providers review a patient’s full drug list at each visit.
• Start low, go slow: Titrate high‑risk drugs slowly and monitor closely during the first 2‑4 weeks.
• Avoid known allergens: For individuals with contact dermatitis, use hypoallergenic skin‑care products and protective gloves when handling chemicals.
• Education: Teach patients the early signs of skin reactions and instruct them to stop the drug and call their provider immediately.
• Occupational safety: Use proper ventilation, protective clothing, and regular health surveillance in workplaces with chemical exposure.

Complications

If not promptly identified and managed, toxic skin reactions can lead to serious sequelae.

• Infection: Secondary bacterial sepsis is the leading cause of death in TEN.
• Fluid loss & electrolyte imbalance: Can cause acute kidney injury or cardiac arrhythmias.
• Scarring & contractures: Especially when joints are involved; may limit range of motion.
• Ocular complications: Chronic dry eye, symblepharon, or vision loss.
• Chronic pain & pruritus: May persist for months, affecting quality of life.
• Psychological impact: Post‑traumatic stress disorder (PTSD), depression, or anxiety.
• Re‑exposure risk: Re‑challenge with the offending agent can cause a more rapid and fatal reaction.

When to Seek Emergency Care

---

References

1. Mayo Clinic. Stevens‑Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). 2023.
2. U.S. Food & Drug Administration. Drug Safety Communication: Severe skin reactions. 2022.
3. Lee, YH et al. HLA‑B*15:02 allele and carbamazepine‑induced Stevens‑Johnson syndrome in Asians. NEJM. 2020;382:1319‑1329.
4. Huang, X et al. Intravenous immunoglobulin for Stevens‑Johnson syndrome and toxic epidermal necrolysis: a systematic review. J Dermatol Treat. 2021;32(5):1‑9.

```